脳血管疾患治療市場：治療モダリティ、製品タイプ、疾患タイプ、エンドユーザー別-2025-2030年の世界予測

脳血管疾患治療市場は、2023年に51億2,000万米ドルと評価され、2024年には54億米ドルに達すると予測され、CAGR 5.76％で成長し、2030年には75億9,000万米ドルに達すると予測されています。

脳血管疾患治療は、脳卒中、動脈瘤、動静脈奇形など、脳を供給する血管に影響を与える障害に対処することを目的とした医療介入および治療アプローチを包含します。この医療分野の必要性は、これらの疾患が世界の障害と死亡の主要原因であり、効果的な治療と技術革新が必要であるため、世界の健康上の負担が大きいことから生じています。その適用範囲は、抗血栓薬やスタチンなどの医薬的介入から、外科的処置や最先端の神経学的機器に至るまで、広範囲に及ぶ。最終用途の範囲には、治療後のケアと回復に重点を置く病院、専門クリニック、リハビリセンターが含まれます。

主な成長要因としては、医療用画像技術の進歩、認知度の向上と早期診断への取り組み、高血圧や糖尿病などの生活習慣に関連する危険因子の有病率の上昇などが挙げられます。遠隔医療とAI主導の診断ツールの統合は、早期発見率と個別化された治療計画を強化する有望な機会を提供します。さらに、低侵襲手術手技の採用が拡大していることも、堅調な市場機会をもたらしています。しかし、市場成長は、高い治療費、規制上のハードル、地域によるヘルスケアアクセスの格差などの課題に直面しています。新興諸国における経済的制約や限られた医療インフラは、こうした課題をさらに悪化させています。

潜在的な機会を活用するために、利害関係者は生物医学研究の革新と、十分なサービスを受けていない市場に浸透できる費用対効果の高い治療ソリューションの開発に注力すべきです。神経保護剤の調査や、バーチャルリアリティやロボット工学によるリハビリ技術の強化は、成長可能な分野です。市場はまた、既存の製薬会社と新興のバイオテクノロジー企業の両方が牽引する、急速な進歩と競合情勢を特徴としています。テクノロジー企業とヘルスケア・プロバイダーのコラボレーションやパートナーシップは、患者のニーズによりよく対応する革新的なソリューションを生み出す可能性があります。結論として、脳血管疾患治療市場には大きなビジネスチャンスがあるが、その課題を克服し、イノベーションのための領域を開拓する戦略的アプローチが求められています。

市場力学：急速に進化する脳血管疾患治療市場の主要市場インサイトを公開

脳血管疾患治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 脳血管疾患に関する意識の高まりと早期スクリーニングの重要性
  • 世界の高齢化の進展とヘルスケア支出の増加
• 市場抑制要因
  • 脳血管治療費の高騰
• 市場機会
  • 神経血管治療における実質的な研究開発イニシアティブ
  • 脳血管疾患治療に使用される機器の進歩
• 市場の課題
  • 副作用のリスクと熟練した専門家の不足

ポーターのファイブフォース：脳血管疾患治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：脳血管疾患治療市場における外部からの影響の把握

外部マクロ環境要因は、脳血管疾患治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析脳血管疾患治療市場における競合情勢の把握

脳血管疾患治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス脳血管疾患治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、脳血管疾患治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨脳血管疾患治療市場における成功への道筋を描く

脳血管疾患治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 脳血管疾患に関する意識の高まりと早期スクリーニングの重要性
    • 世界的に高齢化が進み、ヘルスケア費も増加している
  • 抑制要因
    • 脳血管治療の高額な費用
  • 機会
    • 神経血管ケアにおける実質的な研究開発の取り組み
    • 脳血管疾患治療に用いられる機器の進歩
  • 課題
    • 副作用のリスクと熟練した専門家の不足
• 市場セグメンテーション分析
  • 治療法：低侵襲性のため血管内治療の採用が増加
  • エンドユーザー：病院や外科センターにおける脳血管疾患治療の需要増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 脳血管疾患治療市場治療法別

• 血管内手術
• 医療管理
• 外科的介入

第7章 脳血管疾患治療市場：製品別

• デバイス
  • 頸動脈ステント
  • 脳バルーン血管形成術およびステント留置システム
  • 血栓除去装置
  • コイル塞栓デバイス
  • 塞栓保護システム
  • フローダイバータデバイス
  • 頭蓋内ステント
• 薬物治療
  • 抗凝固薬
  • 降圧薬
  • 抗血小板薬
  • コレステロール低下薬
  • 血栓溶解剤

第8章 脳血管疾患治療市場：疾患タイプ別

• 出血性脳卒中
• 虚血性脳卒中
• 一過性脳虚血発作（TIA）

第9章 脳血管疾患治療市場：エンドユーザー別

• 外来診療センター
• 病院と外科センター
• 調査室および学術機関

第10章 南北アメリカの脳血管疾患治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の脳血管疾患治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの脳血管疾患治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • セレノバス社、急性虚血性脳卒中患者の血行再建用中間カテーテル「セレグライド 71」を発売
  • エンゼン・バイオサイエンス、血管新生性加齢黄斑変性症（AMD）の治療ラニビズマブのバイオシミラーを発売
  • クーパーとインスピラが提携し、南ニュージャージー州で神経科学ケアを拡大
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• AstraZeneca plc
• Bayer AG
• BIOGEN INC.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Daiichi Sankyo Co. Ltd.
• GE HealthCare Technologies Inc.
• Genentech, Inc.
• Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Medtronic plc
• Merck & Co., Inc.
• Penumbra, Inc.
• Pfizer Inc.
• Sangamo Therapeutics, Inc.
• Sanofi SA
• Siemens Healthineers AG
• Sihuan Pharmaceutical Holdings Group Ltd.
• Takeda Pharmaceutical Co. Ltd.
• United Therapeutics Corp.

LIST OF FIGURES

• FIGURE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CEREBROVASCULAR DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CEREBROVASCULAR DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CEREBROVASCULAR DISEASES TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY MEDICAL MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CAROTID STENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CEREBRAL BALLOON ANGIOPLASTY AND STENTING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CLOT RETRIEVAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY FLOW DIVERTER DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY INTRACRANIAL STENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TRANSIENT ISCHEMIC ATTACK (TIA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 56. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 57. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 58. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 59. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 88. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 89. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 90. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 91. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 94. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 95. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 96. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 97. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 197. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 198. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 199. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 200. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 201. ITALY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 220. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 221. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 222. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 223. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 224. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 225. POLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 227. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 228. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 229. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 230. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 231. QATAR CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 286. CEREBROVASCULAR DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 287. CEREBROVASCULAR DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Cerebrovascular Diseases Treatment Market was valued at USD 5.12 billion in 2023, expected to reach USD 5.40 billion in 2024, and is projected to grow at a CAGR of 5.76%, to USD 7.59 billion by 2030.

Cerebrovascular diseases treatment encompasses the medical interventions and therapeutic approaches aimed at addressing disorders that impact the blood vessels supplying the brain, including strokes, aneurysms, and arteriovenous malformations. This medical field's necessity arises from the significant global health burden these diseases pose, as they are leading causes of disability and mortality worldwide, necessitating effective treatments and innovations. The application scope covers a wide range, from pharmaceutical interventions, such as antithrombotics and statins, to surgical procedures and cutting-edge neurological devices. The end-use scope involves hospitals, specialized clinics, and rehabilitation centers focusing on post-treatment care and recovery.

Key growth factors include advances in medical imaging technology, increasing awareness and early diagnosis initiatives, and the rising prevalence of lifestyle-related risk factors, such as hypertension and diabetes. The integration of telemedicine and AI-driven diagnostic tools offers promising opportunities to enhance early detection rates and personalized treatment plans. Additionally, the growing adoption of minimally invasive surgical techniques presents a robust market opportunity. However, market growth faces challenges such as high treatment costs, regulatory hurdles, and disparities in healthcare access across different regions. Economic constraints and limited healthcare infrastructure in developing countries further exacerbate these challenges.

To leverage potential opportunities, stakeholders should focus on innovation in biomedical research and the development of cost-effective treatment solutions that can penetrate underserved markets. Research into neuroprotective agents and the enhancement of rehabilitation techniques through virtual reality and robotics represents viable areas for growth. The market is also characterized by rapid advancements and a competitive landscape, driven by both established pharmaceutical companies and emerging biotech firms. Collaborations and partnerships between technology firms and healthcare providers can yield innovative solutions that better address patient needs. In conclusion, the cerebrovascular disease treatment market presents substantial opportunities, but demands strategic approaches to navigate its challenges and exploit areas for innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cerebrovascular Diseases Treatment Market

The Cerebrovascular Diseases Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing awareness regarding cerebrovascular diseases and the importance of early screening
  • The rising aging population globally and the increasing healthcare expenditures
• Market Restraints
  • High cost of cerebrovascular treatment
• Market Opportunities
  • Substantial R&D initiatives in neurovascular care
  • Advancements in devices used for cerebrovascular disease treatment
• Market Challenges
  • Risk of side effects and lack of skilled professional

Porter's Five Forces: A Strategic Tool for Navigating the Cerebrovascular Diseases Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cerebrovascular Diseases Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cerebrovascular Diseases Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cerebrovascular Diseases Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cerebrovascular Diseases Treatment Market

A detailed market share analysis in the Cerebrovascular Diseases Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cerebrovascular Diseases Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cerebrovascular Diseases Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cerebrovascular Diseases Treatment Market

A strategic analysis of the Cerebrovascular Diseases Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cerebrovascular Diseases Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca, AstraZeneca plc, Bayer AG, BIOGEN INC., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., GE HealthCare Technologies Inc., Genentech, Inc., Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Medtronic plc, Merck & Co., Inc., Penumbra, Inc., Pfizer Inc., Sangamo Therapeutics, Inc., Sanofi SA, Siemens Healthineers AG, Sihuan Pharmaceutical Holdings Group Ltd., Takeda Pharmaceutical Co. Ltd., and United Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the Cerebrovascular Diseases Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Modality, market is studied across Endovascular Procedures, Medical Management, and Surgical Intervention.
• Based on Products, market is studied across Devices and Drug Medication. The Devices is further studied across Carotid Stents, Cerebral Balloon Angioplasty and Stenting Systems, Clot Retrieval Devices, Coil Embolization Devices, Embolic Protection Systems, Flow Diverter Devices, and Intracranial Stents. The Drug Medication is further studied across Anticoagulants, Antihypertensive Drugs, Antiplatelet Drugs, Cholesterol-lowering Drugs, and Thrombolytics.
• Based on Disease Type, market is studied across Hemorrhagic Stroke, Ischemic Stroke, and Transient Ischemic Attack (TIA).
• Based on End-user, market is studied across Ambulatory Care Centers, Hospitals & Surgical Centers, and Research Laboratories & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness regarding cerebrovascular diseases and the importance of early screening
    • 5.1.1.2. The rising aging population globally and the increasing healthcare expenditures
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of cerebrovascular treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Substantial R&D initiatives in neurovascular care
    • 5.1.3.2. Advancements in devices used for cerebrovascular disease treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Risk of side effects and lack of skilled professional
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Modality: Growing adoption of endovascular procedures owing to their minimally invasive nature
  • 5.2.2. End-user: Increasing need for cerebrovascular diseases treatment in hospitals and surgical centers
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cerebrovascular Diseases Treatment Market, by Treatment Modality

• 6.1. Introduction
• 6.2. Endovascular Procedures
• 6.3. Medical Management
• 6.4. Surgical Intervention

7. Cerebrovascular Diseases Treatment Market, by Products

• 7.1. Introduction
• 7.2. Devices
  • 7.2.1. Carotid Stents
  • 7.2.2. Cerebral Balloon Angioplasty and Stenting Systems
  • 7.2.3. Clot Retrieval Devices
  • 7.2.4. Coil Embolization Devices
  • 7.2.5. Embolic Protection Systems
  • 7.2.6. Flow Diverter Devices
  • 7.2.7. Intracranial Stents
• 7.3. Drug Medication
  • 7.3.1. Anticoagulants
  • 7.3.2. Antihypertensive Drugs
  • 7.3.3. Antiplatelet Drugs
  • 7.3.4. Cholesterol-lowering Drugs
  • 7.3.5. Thrombolytics

8. Cerebrovascular Diseases Treatment Market, by Disease Type

• 8.1. Introduction
• 8.2. Hemorrhagic Stroke
• 8.3. Ischemic Stroke
• 8.4. Transient Ischemic Attack (TIA)

9. Cerebrovascular Diseases Treatment Market, by End-user

• 9.1. Introduction
• 9.2. Ambulatory Care Centers
• 9.3. Hospitals & Surgical Centers
• 9.4. Research Laboratories & Academic Institutes

10. Americas Cerebrovascular Diseases Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cerebrovascular Diseases Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cerebrovascular Diseases Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Cerenovus Launched Cereglide 71 Intermediate Catheter for Revascularization in Patients with Acute Ischemic Stroke
  • 13.3.2. Enzene Biosciences Launched Biosimilar to Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration (AMD)
  • 13.3.3. Cooper And Inspira Partner to Expand Neuroscience Care In South Jersey
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Amgen Inc.
• 4. AstraZeneca
• 5. AstraZeneca plc
• 6. Bayer AG
• 7. BIOGEN INC.
• 8. Boehringer Ingelheim International GmbH
• 9. Bristol-Myers Squibb Co.
• 10. Daiichi Sankyo Co. Ltd.
• 11. GE HealthCare Technologies Inc.
• 12. Genentech, Inc.
• 13. Hoffmann-La Roche Ltd.
• 14. Johnson & Johnson Services, Inc.
• 15. Medtronic plc
• 16. Merck & Co., Inc.
• 17. Penumbra, Inc.
• 18. Pfizer Inc.
• 19. Sangamo Therapeutics, Inc.
• 20. Sanofi SA
• 21. Siemens Healthineers AG
• 22. Sihuan Pharmaceutical Holdings Group Ltd.
• 23. Takeda Pharmaceutical Co. Ltd.
• 24. United Therapeutics Corp.